Showing results (121-130 of 183) with videos related to

Sort By:
Pageof 19
The Lancet. Oncology|March 16, 2020
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 studySandra M Swain, David Miles, Sung-Bae Kim, et al.
Breast Cancer Research and Treatment|January 11, 2016
Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclinesAna Barac, Filipa Lynce, Karen L Smith, et al.
Cancer Treatment Reviews|April 17, 2022
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and managementSandra M Swain, Mizuki Nishino, Lisa H Lancaster, et al.
Cancer|June 17, 2014
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancerPeter A Kaufman, Kenneth J Bloom, Howard Burris, et al.
Clinical and Translational Science|February 8, 2025
A Randomized Hybrid-Effectiveness Trial Comparing Pharmacogenomics (PGx) to Standard Care: The PGx Applied to Chronic Pain Treatment in Primary Care (PGx-ACT) TrialD Max Smith, Rut Beyene, Paul Kolm, et al.
Cancers|June 10, 2022
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast CancerChau Dang, Michael S Ewer, Suzette Delaloge, et al.
JCO Precision Oncology|January 31, 2025
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast CancersArielle L Heeke, Andrew Elliott, Kaitlyn O'Keefe, et al.
Clinical Breast Cancer|June 21, 2011
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research GroupPriya Rastogi, Marc E Buyse, Sandra M Swain, et al.
Breast Cancer Research and Treatment|January 14, 2016
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and AxlJennifer L Dine, Ciara C O'Sullivan, Donna Voeller, et al.
Anti-Cancer Drugs|August 24, 2013
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxelJavier Cortés, Sandra M Swain, Iveta Kudaba, et al.
Pageof 19